<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> drug tirilazad mesylate (U-74006F) on histopathological and neurological outcome 3 days after permanent middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion was evaluated in rats </plain></SENT>
<SENT sid="1" pm="."><plain>Several previous studies have demonstrated the efficacy of tirilazad in reducing <z:mpath ids='MPATH_124'>infarct</z:mpath> size when administered before and during <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion, whereas post-treatment may be less effective in permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We sought to determine if a protective effect of tirilazad could be demonstrated when administered after the insult only </plain></SENT>
<SENT sid="3" pm="."><plain>U-74006F (3 mg/kg, i.v.) or <z:mp ids='MP_0001924'>sterile</z:mp> vehicle, was randomly given to rats 10 minutes and 3 hours after permanent <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion produced by transcranial proximal electrocauterization </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume and hemisphere volumes were estimated blindly from histological sections of defined levels of the brain after 72 h of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Neurological score was determined blindly 1, 2, and 3 days after insult </plain></SENT>
<SENT sid="6" pm="."><plain>There was no significant difference in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, volume of non-infarcted tissue, or neurological score between the tirilazad and placebo-treated rats </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, our results support the conception that post-treatment with tirilazad mesylate is not efficacious in reducing <z:mpath ids='MPATH_124'>infarct</z:mpath> size in permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, while pre-treatment, as reported by other groups, appears to be effective in both permanent and temporary focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> models </plain></SENT>
<SENT sid="8" pm="."><plain>In temporary focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, the limited data available suggest that also post-treatment with tirilazad may prove to be neuroprotective </plain></SENT>
</text></document>